Skip to main content

Advertisement

Table 1 Baseline characteristics of 45 patients with locally advanced rectal cancer enrolled in the present study

From: Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study

Characteristic No. of patients (%)
Age (years)
 ≤ 60 37 (82.2)
 > 60 8 (17.8)
Gender
 Male 25 (55.6)
 Female 20 (44.4)
CEA (mg/mL)
 < 5.00 28 (62.2)
 ≥ 5.00 17 (37.8)
CA19-9 (μg/mL)
 < 27 31 (68.9)
 ≥ 27 14 (31.1)
Clinical T category
 T2 1 (2.2)
 T3 18 (40.0)
 T4a 21 (46.7)
 T4b 5 (11.1)
Clinical N category
 N0 5 (11.1)
 N1 15 (33.3)
 N2 25 (55.6)
Clinical disease category
 Stage II 5 (11.1)
 Stage III
  IIIA 1 (2.2)
  IIIB 12 (26.7)
  IIIC 27 (60)
Location from anal verge (cm)
 0–5 27 (60.0)
 > 5–10 15 (33.3)
 > 10 3 (6.7)
Tumor differentiation
 Well differentiated (G1) 2 (4.4)
 Moderately differentiated (G2) 28 (62.2)
 Poor differentiated (G3) 5 (11.1)
 Other or missing 10 (22.2)